Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy

Elsevier

Available online 21 December 2021

Drug Discovery TodayHighlights•

Discusses the epigenetic mechanism in pancreatic cancer (PC).

Explores the metastatic role of epigenetics in PC.

The Highlights the importance of epigenetic targets in PC.

Identifies and discusses the current clinical trial epigenetic inhibitors for PC therapy.

Abstract

Pancreatic cancer (PC) is an aggressive disease characterized by high mortality. Diagnosis at advanced stage, resistance, and recurrence are major hurdles for PC therapy and contribute to poor survival rate. Mutations in tumor-promoting kinases and epigenetic dysregulation in tumor suppressor genes are hallmarks of PC and can be used for diagnosis and therapy. In this review, we highlight dysregulated genes associated with epigenetic mechanisms, including DNA methylation and histone acetylation, involved in PC progression and resistance. We also explore epigenetic drugs currently in clinical trials. Combining epigenetic drugs and targeted therapies might represent a promising approach for PC.

Keywords

Pancreatic cancer

DNMTi

HDACi

DNA methylation

histone acetylation

epigenetics

View full text

© 2021 Elsevier Ltd. All rights reserved.

留言 (0)

沒有登入
gif